Translating Cellular Reprogramming into Efficacious and Scalable Cell Therapies for Immuno-Oncology

Time: To be announced
To be announced
Dr Alessandra De Riva


Adoptive cell therapy has arisen as a novel treatment for B cell malignancies, however, its clinical and commercial success still presents considerable challenges in accessibility for patients and questions regarding the bypassing of patients’ immune systems. In the pursuit of next-generation products, the field continues to explore the therapeutic potential of different immune cell types, sub-types and the numerous modifications necessary to improve the efficacy, safety and scalability of treatments, as well as expand application into solid tumors. The advent of cellular reprogramming as a source of clinically valuable immune cell types is likely to address many of the scalability challenges associated with the current autologous approaches, however, with the power to produce and maintain any cell type from any other, the question remains, how do we translate these into viable cell and gene therapies.

In this session we explore the immuno-oncology landscape, review current developmental trends and provide an update on the translation of our systematic approach to cellular reprogramming, either ex vivo or in vivo, into transformative therapies for oncology and other disease areas with high unmet clinical need.
To view the video assoicated with this lecture click here

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021